Annmarie Bankston
Family · Albemarle, NCNPI 1437895232
Payments from drug & device makers
Across 130 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$408
- Gilead$311
- Novo Nordisk$309
- Lilly USA, LLC$278
- AstraZeneca$146
- GSK$125
- plus $454 from 9 others
What the payments were for
- Food & beverage$2,031100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 32 | $408 |
| Gilead | 12 | $311 |
| Novo Nordisk | 30 | $309 |
| Lilly USA, LLC | 17 | $278 |
| AstraZeneca | 9 | $146 |
| GSK | 6 | $125 |
| Otsuka America Pharmaceutical, Inc. | 6 | $122 |
| Orexo US, Inc. | 4 | $82 |
| Mylan Specialty L.p. | 3 | $56 |
| Amgen | 3 | $55 |
| Boehringer Ingelheim | 3 | $45 |
| Lundbeck LLC | 2 | $34 |
| Alkermes, Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $14 |
How this compares
$2,031 in reported general payments places this provider in the 80th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 88 | $57,293 |
| MounjaroTirzepatide | 47 | $52,501 |
| EliquisApixaban | 42 | $46,824 |
| RexultiBrexpiprazole | 25 | $40,624 |
| JardianceEmpagliflozin | 41 | $37,519 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 179 | $28,539 |
| OzempicSemaglutide | 21 | $23,581 |
| TrulicityDulaglutide | 12 | $22,064 |
| BelbucaBuprenorphine Hcl | 19 | $18,352 |
| MyrbetriqMirabegron | 16 | $14,136 |
| VascepaIcosapent Ethyl | 31 | $13,492 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 27 | $12,174 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $12,114 |
| FarxigaDapagliflozin Propanediol | 11 | $11,048 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $9,390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $278 | $74,56659 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $125 | $63,211100 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $122 | $40,62425 claims |
| Boehringer IngelheimJardiance | $45 | $37,51941 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $146 | $32,55267 claims |
| Novo NordiskOzempic | $309 | $23,58121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,522 family providers in North Carolina.
Other family in Albemarle
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.